Guardant Health, Inc. filings document a Nasdaq-listed precision oncology company that reports results for Oncology, Screening, and Biopharma & Data activities. Its 8-K filings furnish quarterly and annual financial results, preliminary financial information, Regulation FD presentation materials, material agreements, officer changes, and securities offering disclosures.
The company’s proxy materials cover annual meeting voting matters, board and governance information, executive compensation and stockholder proposals. Registration and offering-related filings describe common stock issuance under a shelf registration statement, while recurring disclosures address capital structure, operating outlook, clinical and regulatory updates, and the use of its blood and tissue testing portfolio.
Guardant Health reported second-quarter 2026 revenue of $335.0 million, up 44% year over year, led by oncology revenue of $219.1 million and screening revenue of $52.9 million, which grew over 250%. Total oncology tests reached about 104,000, while Shield screening tests increased to about 66,000. Non-GAAP gross margin improved to 67%.
GAAP net loss widened to $120.1 million (‑$0.90 per share), with non-GAAP net loss of $56.2 million and free cash flow of ‑$69.5 million. Cash, cash equivalents and restricted cash were $1.2 billion as of June 30, 2026.
The company raised full‑year 2026 revenue guidance to $1.34–$1.36 billion, implying 36%–38% growth, with higher expected oncology and Shield volumes. Recent milestones include multiple FDA approvals for Guardant360 assays, Shield’s inclusion in American Cancer Society colorectal screening guidelines, and initial commercial coverage for Shield from UnitedHealth Group.
BlackRock, Inc. filed an amended Schedule 13G reporting its passive ownership of common stock of Guardant Health, Inc. BlackRock beneficially owns 6,895,256 shares, representing 5.2% of Guardant Health’s outstanding common stock.
BlackRock reports sole voting power over 6,667,643 shares and sole dispositive power over 6,895,256 shares, with no shared voting or dispositive power. Various underlying clients and investors may receive dividends or sale proceeds, but no single person has more than five percent of Guardant Health’s outstanding common shares.
Guardant Health director Roberto Mignone exercised a restricted stock unit award on July 21, 2026, converting 264 Restricted Stock Units into 264 shares of Common Stock at $0.00 per share. Following this transaction, he directly holds 9,746 Common shares and 7,128 Restricted Stock Units. The RSU grant, awarded on November 8, 2024, vests over four years, with 25% vesting on October 21, 2025 and the remaining 75% vesting monthly over the subsequent three years. The transaction was not marked as made under a Rule 10b5-1 trading plan, as the related checkbox was left unchecked.
Guardant Health, Inc. director Manuel Hidalgo Medina reported the vesting and settlement of 232 Restricted Stock Units into 232 shares of common stock on July 17, 2026. After these transactions he directly holds 5,306 common shares and 5,569 remaining RSUs from a four-year grant awarded July 17, 2024.
Guardant Health director Tariq Musa reported transactions in company equity. On July 15, 2026, he converted 250 Restricted Stock Units into 250 shares of common stock at no cash cost, leaving 1,999 RSUs outstanding. On July 16, he sold 116 shares of common stock in an open-market sale at $163.29 per share and held 11,182 shares afterward.
Guardant Health, Inc. shareholder Musa Tariq is reported in a Form 144 as intending to sell an amount of 116 common shares through Charles Schwab & Co., Inc. on NASDAQ, with a referenced value of $18,942.00 and an associated date of July 16, 2026.
These securities are described as common stock acquired on July 15, 2026 via a Restricted Stock Lapse, categorized as Equity Compensation. The filing also lists securities sold during the past three months: amounts of 116 with dollar values of $9,840.00, $11,131.00 and $15,102.00 on April 16, May 18 and June 16, 2026, and an amount of 1,951 with a dollar value of $255,893.00 on June 22, 2026.
Guardant Health Chief Legal Officer John G. Saia reported compensation-related stock activity tied to restricted stock units (RSUs). On 2026-07-01, several RSU awards vested and converted into a total of 7,063 shares of Guardant Health common stock at a stated price of $0.00 per share.
To cover tax obligations from this vesting, the company retained 3,707 shares at a price of $170.77 per share, according to the filing footnotes. These transactions reflect RSU vesting, derivative exercises, and tax withholding, not open-market purchases or sales.
Guardant Health, Inc. Chief People Officer Terilyn J. Monroe reported routine equity compensation activity. On July 1, 2026, restricted stock units converted into a total of 4,020 shares of Common Stock, reflecting scheduled vesting of prior awards. The company retained 2,099 shares at $170.77 per share to cover Ms. Monroe’s tax withholding obligations, rather than through an open-market sale. Following these transactions, she continues to hold both common shares and unvested restricted stock units as part of her compensation.
Guardant Health, Inc. Chief Information Officer Kumud Kalia reported routine equity compensation activity. On 2026-07-01, several batches of restricted stock units vested and were converted into a total of 6,046 shares of common stock at a conversion price of $0.00 per share.
To cover associated tax obligations from this vesting, 3,066 shares of common stock were withheld by the company at a value of $170.77 per share, as described in the footnotes. These transactions reflect compensation-related vesting and tax withholding rather than open-market buying or selling.
Guardant Health, Inc. Chief Commercial Officer Chris Freeman reported compensation-related equity activity involving restricted stock units. On July 1, 2026, RSU awards vested and were converted into a total of 7,414 shares of common stock, reflecting derivative exercises rather than open-market purchases.
To cover tax obligations arising from this vesting, 3,141 shares of common stock were retained by the company at a value of $170.77 per share, as noted in the footnotes. The transactions do not include any open-market buying or selling, and are characterized as routine equity compensation and tax withholding events.